Author + information
- Received August 26, 2010
- Revision received November 1, 2010
- Accepted November 9, 2010
- Published online February 15, 2011.
- Savina Nodari, MD⁎,
- Marco Triggiani, MD⁎,
- Umberto Campia, MD‡,
- Alessandra Manerba, MD⁎,
- Giuseppe Milesi, MD⁎,
- Bruno M. Cesana, MD†,
- Mihai Gheorghiade, MD‡,⁎ ( and )
- Livio Dei Cas, MD⁎
- ↵⁎Reprint requests and correspondence:
Dr. Mihai Gheorghiade, Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, 645 North Michigan Avenue, Suite 1006, Chicago, Illinois 60611
Presented at the Late Breaking Clinical Trial of the 14th Annual Scientific Meeting of the Heart Failure Society of America, September 12–15, 2010, San Diego, California.
Objectives This study was designed to test the effects of n-3 polyunsaturated fatty acids (PUFAs) on left ventricular (LV) systolic function in chronic heart failure (HF) due to nonischemic dilated cardiomyopathy (NICM).
Background One hundred thirty-three patients with NICM and minimal symptoms on standard therapy were randomized to 2 g of n-3 PUFAs or placebo. LV function and functional capacity were assessed prospectively by echocardiography and cardiopulmonary exercise testing at baseline and at 12 months after randomization.
Methods Patients with chronic HF due to NICM and minimal symptoms while receiving evidence-based therapy were enrolled. LV function and functional capacity were assessed prospectively by echocardiography, cardiopulmonary exercise test, and New York Heart Association functional class at baseline and at 12 months after randomization to either 2 g of n-3 PUFAs or placebo.
Results At 12 months after randomization, the n-3 PUFAs group and the placebo group differed significantly (p <0.001) in regard to: 1) LV ejection fraction (increased by 10.4% and decreased by 5.0%, respectively); 2) peak VO2 (increased by 6.2% and decreased by 4.5%, respectively); 3) exercise duration (increased by 7.5% and decreased by 4.8%, respectively); and 4) mean New York Heart Association functional class (decreased from 1.88 ± 0.33 to 1.61 ± 0.49 and increased from 1.83 ± 0.38 to 2.14 ± 0.65, respectively). The hospitalization rates for HF were 6% in the n-3 PUFAs and 30% in the placebo group (p = 0.0002).
Conclusions In patients with NICM and minimal symptoms in response to evidence-based medical therapy, n-3 PUFAs treatment increases LV systolic function and functional capacity and may reduce hospitalizations for HF. Given these promising results, larger studies are in order to confirm our findings.
- functional capacity
- heart failure
- nonischemic myocardial function
- n-3 PUFAs
- NYHA functional class
This study was funded by a grant from the “Centro per lo Studio ed il Trattamento dello Scompenso Cardiaco” of the University of Brescia, Brescia, Italy. Dr. Gheorghiade is a consultant for Bayer Schering Pharma AG, Debiopharm SA, Medtronic, Novartis, Otsuka Pharmaceuticals, Sigma-Tau Pharmaceuticals, Solvay Pharmaceuticals (now Abbott), and PeriCor Therapeutics, and has received travel compensation from Bayer Schering Pharma, Novartis, and Sigma-Tau Pharmaceuticals. All other authors have reported that they have no relationships to disclose.
- Received August 26, 2010.
- Revision received November 1, 2010.
- Accepted November 9, 2010.
- American College of Cardiology Foundation